Wenn ich sehe, Aurora mit guter Meldung nicht einmal 1% Plus, Cronos ohne Meldung 3,5% Plus.
Aber ich denke mir, wenn ich jetzt von Aurora in Cronos wechsle, wird Aurora genau dann anspringen. Von der Performance her, ist Aurora von den Top5-Cannabis-Herstellern derjenige, der mit Abstand die schlechteste Performance aufweist. Vielleicht sollte sich Aurora um einen Investor umsehen - egal um welchen Preis, damit der Kurs anspringt.
Quote: (Albany, NY) The Senate today passed legislation that will address the racial disparities that are present in New York?s antiquated marijuana drug laws. New York?s existing marijuana laws disproportionately affect the African American and Latinx communities. This monumental legislation will decriminalize small amounts of marijuana and establish procedures for record expungements for both past and future convictions.
: Auszug von 5 Punkten von Aurora zum mit verfolgen!
Für große Marktteilnehmer denke ich ist der Eintritt in den US-Markt sehr wichtig und ich bin mir sicher dass Schritt für Schritt sich vorab positioniert wird: Der frühe Vogel fängt den Wurm !
One of the bigger questions on the minds of Wall Street and investors is when Aurora Cannabis will detail its entrance into the U.S. market. We've already seen close to half of Aurora's major competitors enter the U.S. hemp industry, thereby laying the processing and distribution infrastructure that would be needed if and when the U.S. federal government changes its tune on marijuana at the federal level. But as of now, Aurora hasn't outlined its plans for the U.S. market.
Back in mid-January, Aurora's chief corporate officer, Cam Battley, told Business Insider in an interview that "We'll be unveiling our hemp-derived CBD [cannabidiol] strategy to enter the U.S. market over the next few months." However, that time frame has come and gone with little mention of what Aurora's next steps are. As a company that prides itself on geographic expansion, it's almost a certainty that we'll hear about Aurora's U.S. CBD-market plans in the second half of 2019.
Aurora paid C$290 million for ICC Labs, and in my view it was well worth it; although I believe the Latin American market will take more time to develop than some of its European counterparts, even though the continent is more liberal in its outlook concerning cannabis than other regions of the world.
Part of that comes from the need to build up various aspects of infrastructure associated with the industry, as well as boost the amount of production capacity to meet demand in the market, along with competing in other markets.
In 2018 the Latin American market was valued at $125 million, and is projected to grow to $12.7 billion by 2028. I think it could be far larger than that.
Medical cannabis has been considered to be the largest segment of that market, but the rapid increase in production capacity in Columbia will probably change the product mix going forward, as it boosts low-cost recreational pot exports over time.
: Aurora bald profitabel ?! Wäre auch Einzigartig
Aurora Cannabis Could be Among the First Marijuana Sellers to Turn a Profit
-- Barrons.com BY Dow Jones & Company, Inc. ? 2:49 PM ET 06/24/2019
Aurora Cannabis ( ACB ) is on track to be the one of the first big marijuana firms to turn a profit. That could come as soon as this quarter, according to Cowen analyst Vivien Azer. The back story. Aurora Cannabis ( ACB ) sold 9 metric tons of marijuana last quarter, but that wasn't enough to beat Wall Street's bar for revenue and adjusted earnings. At the time, BMO Capital Markets analyst Tamy Chen was concerned about a lack of supply that could hinder its path to profitability.
Aurora stock closed at $9.25 3 months ago. Since then it has shed a fifth of its value, sinking to $ 7.30 at Friday's close. Some have been bullish, Bank of America Merrill Lynch and Cowen among them, while others, including Stifel's Andrew Carter, prefer rival Canopy Growth. What's new. Azer called Aurora stock her top marijuana pick, in a note to clients on Monday. She wrote that while other firms struggle with larger losses, Aurora could reach positive earnings before interest, taxes, depreciation, and amortization, or Ebitda, this quarter. Compare that with Canopy, which posted an expanded Ebitda loss of 98 million Canadian dollars (US$74.3 million) when in reported fiscal fourth quarter earnings last week. "At a time when EBITDA losses across the industry are elevated, we have a strong appreciation for
ACB's operational rigor," Azer wrote. She noted that Aurora holds a No. 2 position in recreational-use revenue and is among the best at keeping a variety of products in stock in Ontario, British Columbia, and Alberta. She also said it has the largest cultivation footprint in Canada, which gives the company the infrastructure to increase its revenue in the medical market during a weaker recreational market. Aurora stock was up 2.1% to $7.45 Monday afternoon. The S&P 500 was nearly flat. Looking ahead. Azer maintained an Outperform rating, noting that it should trade at a premium to its peers "given its near term path to profitability in conjunction with strong early stage execution within the nascent Canadian cannabis adult use market."
She said that as the recreational-use market evolves, she looks for better industry supply to support bricks-and- mortar stores and draw more market share from illicit sellers. Health Canada will also begin evaluating second-wave Cannabis products, such as vapes and edibles, in October. The process will take 60 days, meaning those products wouldn't hit the shelves until at least mid to late December. When that does happen, Azer expects Aurora to focus its efforts on vapor, although "they will likely carry a diverse portfolio of products." She said Aurora could add revenue via its operations in Germany and Australia, and attract a big-time strategic partner " likely brokered by strategic advisor Nelson Peltz." Write to Connor Smith at email@example.com
: Is it possible that cannabis will help USA economy
That´s a very interesting Information, I really belive that aurora Cannabis will turn a profit to sellers. I also read one day ago an article (in german) which contained that cannabis-shares could help the economy of the USA with growing. What do you think of that?